Spots Global Cancer Trial Database for leukemia, myeloid
Every month we try and update this database with for leukemia, myeloid cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia | NCT01050036 | Leukemia, Myelo... | autologous hema... | 15 Years - 65 Years | Asan Medical Center | |
| Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) | NCT00034684 | Leukemia Myelodysplastic... Leukemia, Myelo... Blast Crisis Leukemia, Lymph... | Farnesyl Protei... | 18 Years - | Merck Sharp & Dohme LLC | |
| CIML NK Cells With Venetoclax for AML | NCT06152809 | Acute Myeloid L... Acute Myeloid L... Leukemia Leukemia, Myelo... | Cytokine-Induce... Interleukin-2 Venetoclax | 18 Years - | Dana-Farber Cancer Institute | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT | NCT03114670 | Adult Acute Mye... | CD123CAR-41BB-C... | 18 Years - | Affiliated Hospital to Academy of Military Medical Sciences | |
| Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses | NCT02467270 | Myeloid Leukemi... | Ponatinib | 18 Years - | Takeda | |
| Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients | NCT01511289 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Philadelphia Ch... Bone Marrow Dis... Hematologic Dis... | Imatinib Radotinib | 18 Years - | Il-Yang Pharm. Co., Ltd. | |
| A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | NCT02130557 | Leukemia, Myelo... | Bosutinib Imatinib | 18 Years - | Pfizer | |
| Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML) | NCT00822094 | Acute Myeloid L... | CPX-351 Intensive Salva... | 18 Years - 65 Years | Jazz Pharmaceuticals | |
| Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG | NCT02916979 | Leukemia, Lymph... Leukemia, Myelo... Myelodysplastic... Myelofibrosis Lymphoma, Malig... Multiple Myelom... Waldenstrom Mac... | Fludarabine Busulfan Rabbit ATG Methotrexate | 18 Years - 75 Years | Dartmouth-Hitchcock Medical Center | |
| An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® | NCT02455024 | Myeloid Leukemi... | 18 Years - | Takeda | ||
| T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation | NCT00306332 | Leukemia, Myelo... Leukemia, Lymph... Myelodysplastic... Leukemia, Myelo... Lymphoma | T-cell and B-ce... | 18 Years - 65 Years | Radboud University Medical Center | |
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | NCT06001788 | AML AML With Mutate... Hematologic Mal... KMT2Ar NPM1 Mutation MLL Rearrangeme... Leukemia Acute Myeloid L... Leukemia, Myelo... Leukemia, Myelo... Acute Leukemia Neoplasms by Hi... | Ziftomenib Fludarabine Idarubicin Cytarabine Gilteritinib Granulocyte col... | 18 Years - | Kura Oncology, Inc. | |
| Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease | NCT02370888 | Leukemia, Myelo... Myelodysplastic... | Lenalidomide | 18 Years - | University of Florida | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | NCT06001385 | Acute Lymphobla... Acute Myeloid L... Acute Leukemia Myelodysplastic... Chronic Myeloid... Chronic Lymphoc... Myeloproliferat... Lymphoma Chronic Myelomo... Pro-Lymphocytic... Myelofibrosis | Busulfan Fludarabine PBSC Hematopoie... Post-Transplant... Mesna Tacrolimus Mycophenolate M... Patient Reporte... Melphalan Total-body irra... Cyclophosphamid... | 18 Years - | Center for International Blood and Marrow Transplant Research | |
| Chronic Myeloid Leukemia (CML) Real-Life Database | NCT05963061 | Chronic Myeloid... | - | University Hospital, Clermont-Ferrand | ||
| Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase | NCT05143840 | Chronic Myeloid... Adult CML Leukemia, Myelo... Leukemia,Myeloi... | Asciminib Ascimininb + Ni... Asciminib + Ima... Asciminib + Das... | 18 Years - | Augusta University | |
| Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies | NCT02333838 | Leukemia, Myelo... | IV Thiotepa IV Fludarabine IV Busulfan IV Anti-thymocy... | 18 Years - 65 Years | Assistance Publique - Hôpitaux de Paris | |
| An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation | NCT02577406 | Leukemia, Myelo... Isocitrate Dehy... | AG-221 BSC Azacitidine Low-dose cytara... Intermediate-do... | 60 Years - | Celgene | |
| Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML | NCT00568633 | Leukemia, Myelo... Leukemia Acute Myeloid L... | Allogeneic HSCT Anti-thymocyte ... Cyclosporine (C... Mycophenolate m... Total lymphoid ... Methylprednisol... Best standard c... | 50 Years - 75 Years | Stanford University | |
| An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® | NCT02455024 | Myeloid Leukemi... | 18 Years - | Takeda | ||
| Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | NCT03578367 | CML Chronic Myeloge... Leukemia, Myelo... Hematologic Dis... | Asciminib add-o... Imatinib Nilotinib Asciminib singl... | 18 Years - | Novartis | |
| A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia | NCT00233909 | Leukemia, Myelo... | Zosuquidar gemtuzumab ozog... | 18 Years - | Kanisa Pharmaceuticals | |
| A Multicentre, Retrospective Study to Evaluate the Outcome of HSCT Mismatch Unrelated Donors | NCT04598789 | Leukemia, Myelo... | no intervention | - | Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna | |
| High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML | NCT03080922 | Leukemia, Myelo... | hematopoietic s... | 15 Years - 85 Years | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | |
| Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders | NCT01392989 | Neural Tube Def... Anemia Leukemia, Myelo... Bone Marrow Tra... Myelodysplastic... Myeloproliferat... | CIK cells Cyclosporine Mycophenolate M... Thymoglobulin Total Lymphoid ... | 50 Years - | Stanford University | |
| Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia | NCT00611247 | Leukemia, Myelo... | Temozolomide | 60 Years - | Stanford University | |
| A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) | NCT01667133 | Chronic Myeloid... Philadelphia Ch... | ponatinib - Pha... ponatinib - Pha... | 18 Years - | Takeda | |
| Chronic Myeloid Leukemia (CML) Real-Life Database | NCT05963061 | Chronic Myeloid... | - | University Hospital, Clermont-Ferrand | ||
| A Multicentre, Retrospective Study to Evaluate the Outcome of HSCT Mismatch Unrelated Donors | NCT04598789 | Leukemia, Myelo... | no intervention | - | Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna | |
| Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | NCT03578367 | CML Chronic Myeloge... Leukemia, Myelo... Hematologic Dis... | Asciminib add-o... Imatinib Nilotinib Asciminib singl... | 18 Years - | Novartis | |
| A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia | NCT02627677 | Chronic Phase C... | Ponatinib 30 mg... Ponatinib 15 mg... Nilotinib 400 m... | 18 Years - | Takeda | |
| A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia | NCT02538965 | Leukemia, Myelo... | Lenalidomide | 1 Year - 18 Years | Celgene | |
| Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients | NCT01511289 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Philadelphia Ch... Bone Marrow Dis... Hematologic Dis... | Imatinib Radotinib | 18 Years - | Il-Yang Pharm. Co., Ltd. | |
| Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes | NCT00451997 | Leukemia, Myelo... Myelodysplastic... | Gleevec Ara-C | 60 Years - | M.D. Anderson Cancer Center | |
| A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) | NCT01667133 | Chronic Myeloid... Philadelphia Ch... | ponatinib - Pha... ponatinib - Pha... | 18 Years - | Takeda | |
| Endogenous Retroviruses in Acute Myeloid Leukemia | NCT04406207 | Leukemia, Myelo... | Demonstration o... | 18 Years - | Hospices Civils de Lyon | |
| Biomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic Leukemias | NCT01144793 | Leukemia, Lymph... Leukemia, Myelo... | 18 Years - | Stanford University | ||
| Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies | NCT02333838 | Leukemia, Myelo... | IV Thiotepa IV Fludarabine IV Busulfan IV Anti-thymocy... | 18 Years - 65 Years | Assistance Publique - Hôpitaux de Paris | |
| Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological Disease | NCT04039100 | Multiple Myelom... Lymphoma Bone Marrow Tra... Neoplasms Hematologic Dis... Leukemia, Myelo... | Family Caregive... | 18 Years - | Rigshospitalet, Denmark | |
| High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML | NCT03080922 | Leukemia, Myelo... | hematopoietic s... | 15 Years - 85 Years | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | |
| HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide | NCT04904588 | Acute Lymphobla... Acute Myelogeno... Mixed Phenotype... Acute Leukemia Myelodysplastic... Chronic Myeloge... Chronic Lymphoc... Lymphoma | Busulfan Busulfan Fludarabine Total-body irra... Cyclophosphamid... Melphalan PBSC Hematopoie... Bone Marrow Hem... Post-transplant... Mesna Tacrolimus Mycophenolate M... Patient-Reporte... | 1 Year - | Center for International Blood and Marrow Transplant Research | |
| Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase | NCT05143840 | Chronic Myeloid... Adult CML Leukemia, Myelo... Leukemia,Myeloi... | Asciminib Ascimininb + Ni... Asciminib + Ima... Asciminib + Das... | 18 Years - | Augusta University | |
| Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT | NCT03114670 | Adult Acute Mye... | CD123CAR-41BB-C... | 18 Years - | Affiliated Hospital to Academy of Military Medical Sciences | |
| A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML | NCT03417427 | Leukemia, Myelo... | Decitabine and ... Ara-C | 14 Years - 60 Years | Nanfang Hospital, Southern Medical University | |
| Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI | NCT01602952 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Philadelphia Ch... Hematologic Dis... | Radotinib | 18 Years - | Il-Yang Pharm. Co., Ltd. | |
| An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® | NCT02455024 | Myeloid Leukemi... | 18 Years - | Takeda | ||
| Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML | NCT00568633 | Leukemia, Myelo... Leukemia Acute Myeloid L... | Allogeneic HSCT Anti-thymocyte ... Cyclosporine (C... Mycophenolate m... Total lymphoid ... Methylprednisol... Best standard c... | 50 Years - 75 Years | Stanford University | |
| A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | NCT02130557 | Leukemia, Myelo... | Bosutinib Imatinib | 18 Years - | Pfizer | |
| Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients | NCT01511289 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Philadelphia Ch... Bone Marrow Dis... Hematologic Dis... | Imatinib Radotinib | 18 Years - | Il-Yang Pharm. Co., Ltd. | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia | NCT04272125 | Leukemia Leukemia, Myelo... Leukemia, Myelo... | CD123 CAR-T cel... | 3 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia | NCT01050036 | Leukemia, Myelo... | autologous hema... | 15 Years - 65 Years | Asan Medical Center | |
| Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation | NCT05282459 | Leukemia Leukemia, Myelo... Monocytic Leuke... | Enasidenib mesy... | 18 Years - | Stanford University | |
| Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia | NCT00512083 | Leukemia, Myelo... | AS1411 | 18 Years - | Antisoma Research | |
| Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders | NCT01392989 | Neural Tube Def... Anemia Leukemia, Myelo... Bone Marrow Tra... Myelodysplastic... Myeloproliferat... | CIK cells Cyclosporine Mycophenolate M... Thymoglobulin Total Lymphoid ... | 50 Years - | Stanford University | |
| Allo HSCT Using RIC and PTCy for Hematological Diseases | NCT05805605 | Acute Myelogeno... Acute Lymphocyt... Biphenotypic Ac... Undifferentiate... Prolymphocytic ... Chronic Myeloge... Plasma Cell Leu... Myelodysplastic... Leukemia, Myelo... Myelodysplastic... Burkitt Lymphom... Relapsed T-Cell... Relapsed Chroni... Small Lymphocyt... Marginal Zone L... Follicular Lymp... Myeloproliferat... Myelofibrosis | Peripheral Bloo... Allopurinol 300... Fludarabine Cyclophosphamid... Bone Marrow Cel... Total Body Irra... Sirolimus Pill Mycophenolate M... | - 75 Years | Masonic Cancer Center, University of Minnesota | |
| Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia | NCT04272125 | Leukemia Leukemia, Myelo... Leukemia, Myelo... | CD123 CAR-T cel... | 3 Years - 75 Years | Chongqing Precision Biotech Co., Ltd |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
